Journey Medical
DERM
37 hedge funds and large institutions have $14.8M invested in Journey Medical in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
22% more capital invested
Capital invested by funds: $12.2M → $14.8M (+$2.63M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
10.8% more ownership
Funds ownership: 14.64% → 25.44% (+11%)
3% more funds holding
Funds holding: 36 → 37 (+1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.43M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$244K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$122K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$112K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$598K |
| 2 |
Neuberger Berman Group
New York
|
-$196K |
| 3 |
Renaissance Technologies
New York
|
-$176K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$133K |
| 5 |
Walleye Capital
New York
|
-$131K |
DERM Hedge Fund Activity: Q4 2024 in Review
37 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q4 2024, worth a combined $14.8M — up 22% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new DERM positions and 6 closed out — a net gain of 1 holder — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $9.43M. The largest seller was Rosalind Advisors, exiting entirely with an estimated $598K sold.
- 37 institutional investors held Journey Medical (DERM) as of Q4 2024, up from 36 in Q3 2024.
- Funds reported $14.8M of Journey Medical stock for Q4 2024, up 22% quarter-over-quarter.
- 7 funds opened new Journey Medical positions in Q4 2024 and 6 closed out, a net change of +1 holder.
- The largest Journey Medical buyer in Q4 2024 was Tang Capital Management, an estimated $9.43M added.
- The largest Journey Medical seller in Q4 2024 was Rosalind Advisors, an estimated $598K sold.
Based on aggregated 13F filings for Q4 2024.